上海宣泰医药科技股份有限公司2025年度业绩快报公告

Financial Performance Summary - In 2025, the company reported total revenue of 446.50 million yuan, a year-on-year decrease of 12.73% [1] - The net profit attributable to the parent company was 48.95 million yuan, down 61.67% year-on-year, while the net profit after deducting non-recurring gains and losses was 31.38 million yuan, a decline of 72.47% [1][3] - The company's total assets at the end of the reporting period were 1,437.68 million yuan, a decrease of 1.07% year-on-year [2] Key Factors Affecting Performance - The decline in revenue and profit was primarily due to the implementation of the 10th batch of national drug procurement policies, which led to significant price reductions for some products, thereby compressing profit margins [2][3] - Increased competition in the U.S. market and rising tariffs negatively impacted sales and profitability of certain products, such as mesalamine enteric-coated tablets [2][3] - The company adopted a cautious approach by recognizing impairment losses on accounts receivable, inventory, and goodwill, which adversely affected net profit [2][3] Shareholder Equity and Earnings - The equity attributable to the parent company increased by 1.61% year-on-year to 1,293.45 million yuan, while the net asset per share rose to 2.85 yuan, an increase of 1.49% [2] - Basic earnings per share decreased by 60.65%, primarily due to the significant drop in net profit attributable to the parent company [3]